Abiopharma

Evolus Inc (EOLS) Reports Q3 2022 Financial Results Evolus Inc (EOLS) announced its financial results for the period ending Q3 2022. Key Financial Highlights:

• Revenue: 15819
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 84484
  • The company’s lead sales and marketing metrics demonstrated continued momentum in the company’s business during the second quarter. ◦Evolus added 590 new customer accounts in the second quarter, bringing the total base since launch to more than 8,100 purchasing customers with a reorder rate that continues to run above 70%
  • ◦Membership in the Evolus Rewards loyalty program ended the quarter at nearly 390,000 consumers. Through the first half of 2022, approximately 180,000 rewards had been redeemed compared to 100,000 for the first half of
  • ◦During the second quarter, Evolus ran a total of 750 individualized co
    • targeting the millennial consumer using our cost-effective digital platform.” Moatazedi continued, “Based on our year-to-date performance which reflects increasing momentum, our Nuceiva® launch in Europe in the third quarter, and our confidence in a resilient and fundamentally strong aesthetic neurotoxin market, Evolus is on track for another very successful year. We continue to believe we can achieve the upper end of our full-year sales guidance range of $143 to $150 million, which equates to a year-over-year growth rate approaching 50%, and expect our gross margin to step up meaningfully in the fourth quarter when our royalty payment to our largest competitor will end.”Second Quarter 2022